THIRD AMENDMENT TO MASTER SERVICES AGREEMENT
Exhibit 10.12.4
THIRD AMENDMENT TO
MASTER SERVICES AGREEMENT
MASTER SERVICES AGREEMENT
THIS THIRD AMENDMENT TO MASTER SERVICES AGREEMENT (“3rd Amendment”) dated as of June 20, 2016 (“Effective Date”) is
entered into by and between Accredo Health Group, Inc. (“Service Provider”) and Aegerion Pharmaceuticals, Inc., a Delaware corporation with offices at Xxx Xxxx Xxxxxx
Xxxxx 000, Xxxxxxxxx, XX 00000 (“Aegerion”) as successor in interest to AstraZeneca Pharmaceutical LP, a Delaware limited partnership with offices at 0000 Xxxxxxx Xxxx, Xxxxxxxxxx, Xxxxxxxx 00000 (“AstraZeneca”).
WITNESSETH:
WHEREAS, the predecessor in interest to Aegerion and Service Provider entered into a MASTER SERVICES AGREEMENT
with an effective date of December 6, 2013 (the “Agreement”); which was later amended by the 1st Amendment dated January 19, 2014, and the Second Amendment dated June 1,
2014; and
WHEREAS, the Agreement was assigned to Aegerion by AstraZeneca effective January 9, 2015; and
WHEREAS, Aegerion and Service Provider desire to amend the terms of the Agreement as set forth herein.
NOW, THEREFORE, THE PARTIES, intending to be legally bound, agreed to amend the Agreement as follows:
| 1. |
Notwithstanding anything in the Agreement, to the contrary, the parties mutually agree to extend the term of the Agreement until July 31, 2018.
|
| 2. |
Except as modified herein, all other terms of the Agreement remaining full force and effect.
|
IN WITNESS WHEREOF, the parties have hereunto signed this 3rd Amendment effective as of the date set forth above.
|
AEGERION PHARMACEUTICALS, INC.
|
ACCREDO HEALTH GROUP, INC.
|
|
By:
|
/s/ Xxxxxxxxx Xxxxxxxx |
By:
|
/s/ Xxxx Xxxxxx |
|
Name:
|
Xxxxxxxxx Xxxxxxxx |
Name:
|
Xxxx Xxxxxx |
|
Title:
|
VP Pt Engagement |
Title:
|
VP |
|
Date:
|
6/23/16
|
Date:
|
6/20/16
|
